Medicare AdvantagePrior AuthLow impact
Cresemba® (isavuconazonium sulfate) (Revised)
Humana·Infectious Disease, Internal Medicine, Critical Care·Medicare Advantage
Effective date
Feb 25, 2026
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage has revised its Cresemba (isavuconazonium sulfate) coverage policy effective February 25, 2026. The policy maintains prior authorization requirements for invasive aspergillosis and invasive mucormycosis treatment, with a notable exclusion for patients with familial short QT syndrome. The revision updates drug interaction guidance and reinforces hepatic monitoring requirements.
Action Required
By February 25, 2026: Billing team should verify current authorization status for any active Cresemba claims in queue. Ensure all prior authorization requests for Cresemba include documented diagnosis of invasive aspergillosis or invasive mucormycosis and confirm member does not have familial short QT syndrome (exclusion criterion). Update internal policy reference materials to reflect the February 25, 2026 revision date. Pharmacy staff should alert prescribers to the hepatic monitoring requirements and drug interaction warnings, particularly with CYP3A4 inhibitors/inducers and immunosuppressants (tacrolimus, sirolimus, cyclosporine). No workflow changes required; this is a routine policy maintenance update.